Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI
Abstract Background Patients with AKI experience higher rates of heart failure (HF). This study seeks to identify criteria to assess the risk of heart failure post-hospitalization, with a special focus on AKI patients. We hypothesized that the combined use of 9 vascular biomarkers would predict futu...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04169-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344853805105152 |
|---|---|
| author | Audrey A. Shi Anna Simone Andrawis Aditya Biswas Francis P. Wilson Wassim Obeid Heather Thiessen Philbrook Alan S. Go T. Alp Ikizler Edward D. Siew Vernon M. Chinchilli Chi-Yuan Hsu Amit X. Garg W. Brian Reeves David K. Prince Pavan Bhatraju Steve G. Coca Kathleen D. Liu Paul L. Kimmel James S. Kaufman Mark W. Wurfel Jonathan Himmelfarb Chirag R. Parikh Sherry G. Mansour for the ASSESS-AKI Consortium* |
| author_facet | Audrey A. Shi Anna Simone Andrawis Aditya Biswas Francis P. Wilson Wassim Obeid Heather Thiessen Philbrook Alan S. Go T. Alp Ikizler Edward D. Siew Vernon M. Chinchilli Chi-Yuan Hsu Amit X. Garg W. Brian Reeves David K. Prince Pavan Bhatraju Steve G. Coca Kathleen D. Liu Paul L. Kimmel James S. Kaufman Mark W. Wurfel Jonathan Himmelfarb Chirag R. Parikh Sherry G. Mansour for the ASSESS-AKI Consortium* |
| author_sort | Audrey A. Shi |
| collection | DOAJ |
| description | Abstract Background Patients with AKI experience higher rates of heart failure (HF). This study seeks to identify criteria to assess the risk of heart failure post-hospitalization, with a special focus on AKI patients. We hypothesized that the combined use of 9 vascular biomarkers would predict future heart failure events after AKI. Using a study of 1497 hospitalized patients with and without AKI, we found that these 9 vascular biomarkers successfully stratified patients into different risk groups for HF, and were able to improve prediction of HF when added to routine clinical variables. Methods Using the ASSESS-AKI cohort, we performed an unsupervised spectral cluster analysis with 9 plasma biomarkers measured at 3 months post-hospitalization [Angiopoietin (angpt)-1, angpt-2, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-d, VEGF receptor 1 (R1), solubleTie-2 (sTie-2), placental growth factor (PlGF), and basic fibroblast growth factor (bFGF)] in 1,497 patients, half of whom had AKI. We used a Cox regression analysis to evaluate the associations between the clusters and HF. Models were adjusted for demographics, cardiovascular disease risk factors, medications, ICU status, lung disease, sepsis, clinical center, and 3-month post-discharge serum creatinine and proteinuria. We calculated change in the area under the curve (AUC) for the prediction of HF or death at 3 years by adding the biomarkers to a clinical model selected by a penalized regression with LASSO. We also calculated a net reclassification index for the addition of the biomarkers to the clinical model. Results Three biomarker-derived clusters were identified: Cluster 1 [n = 302, Vascular Injury (Injury) Phenotype] had higher levels of injury markers, whereas Cluster 2 [n = 728, Vascular Repair (Repair) Phenotype] had higher levels of repair markers. Cluster 3 (n = 467) had lower levels of all markers (Dormant Phenotype). Across the entire cohort, those with the Injury Phenotype had twofold higher risk of a HF event compared to the Repair Phenotype [aHR 2.24 (95% CI: 1.57–3.19)] and noted in both participants with AKI [aHR 2.12 (95% CI: 1.35–3.34)] and without AKI [aHR 2.94 (95%CI: 1.57–5.50)]. The Dormant Phenotype was associated with higher risk of HF events only in participants without AKI. The AUC for the prediction of HF event or death at 3 years by the biomarkers was 0.76 (95% CI: 0.73–0.80), 0.77 (95% CI: 0.73–0.80) for the clinical model, and 0.80 (95% CI: 0.77–0.83) for the combined model. The addition of the biomarkers significantly improved reclassification of HF event or death. Conclusions Vascular biomarkers can be used to derive phenotypes capable of stratifying future risk of HF events in recently hospitalized patients with or without AKI. |
| format | Article |
| id | doaj-art-45c068f0a52e49beb3bb33c6385c2d9a |
| institution | Kabale University |
| issn | 1471-2369 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj-art-45c068f0a52e49beb3bb33c6385c2d9a2025-08-20T03:42:34ZengBMCBMC Nephrology1471-23692025-06-0126111310.1186/s12882-025-04169-1Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKIAudrey A. Shi0Anna Simone Andrawis1Aditya Biswas2Francis P. Wilson3Wassim Obeid4Heather Thiessen Philbrook5Alan S. Go6T. Alp Ikizler7Edward D. Siew8Vernon M. Chinchilli9Chi-Yuan Hsu10Amit X. Garg11W. Brian Reeves12David K. Prince13Pavan Bhatraju14Steve G. Coca15Kathleen D. Liu16Paul L. Kimmel17James S. Kaufman18Mark W. Wurfel19Jonathan Himmelfarb20Chirag R. Parikh21Sherry G. Mansour22for the ASSESS-AKI Consortium*Department of Internal Medicine, Section of Nephrology, Yale School of MedicineDepartment of Internal Medicine, Section of Nephrology, Yale School of MedicineDepartment of Internal Medicine, Section of Nephrology, Yale School of MedicineDepartment of Internal Medicine, Section of Nephrology, Yale School of MedicineJohns Hopkins UniversityJohns Hopkins UniversityKaiser Permanente Northern CaliforniaVanderbilt UniversityVanderbilt UniversityThe Pennsylvania State UniversityUniversity of California, San FranciscoWestern UniversityThe University of Texas Health Science Center at San AntonioUniversity of WashingtonUniversity of WashingtonIcahn School of Medicine at Mount SinaiUniversity of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney DiseasesVA New York Harbor Healthcare SystemUniversity of WashingtonUniversity of WashingtonJohns Hopkins UniversityDepartment of Internal Medicine, Section of Nephrology, Yale School of MedicineAbstract Background Patients with AKI experience higher rates of heart failure (HF). This study seeks to identify criteria to assess the risk of heart failure post-hospitalization, with a special focus on AKI patients. We hypothesized that the combined use of 9 vascular biomarkers would predict future heart failure events after AKI. Using a study of 1497 hospitalized patients with and without AKI, we found that these 9 vascular biomarkers successfully stratified patients into different risk groups for HF, and were able to improve prediction of HF when added to routine clinical variables. Methods Using the ASSESS-AKI cohort, we performed an unsupervised spectral cluster analysis with 9 plasma biomarkers measured at 3 months post-hospitalization [Angiopoietin (angpt)-1, angpt-2, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-d, VEGF receptor 1 (R1), solubleTie-2 (sTie-2), placental growth factor (PlGF), and basic fibroblast growth factor (bFGF)] in 1,497 patients, half of whom had AKI. We used a Cox regression analysis to evaluate the associations between the clusters and HF. Models were adjusted for demographics, cardiovascular disease risk factors, medications, ICU status, lung disease, sepsis, clinical center, and 3-month post-discharge serum creatinine and proteinuria. We calculated change in the area under the curve (AUC) for the prediction of HF or death at 3 years by adding the biomarkers to a clinical model selected by a penalized regression with LASSO. We also calculated a net reclassification index for the addition of the biomarkers to the clinical model. Results Three biomarker-derived clusters were identified: Cluster 1 [n = 302, Vascular Injury (Injury) Phenotype] had higher levels of injury markers, whereas Cluster 2 [n = 728, Vascular Repair (Repair) Phenotype] had higher levels of repair markers. Cluster 3 (n = 467) had lower levels of all markers (Dormant Phenotype). Across the entire cohort, those with the Injury Phenotype had twofold higher risk of a HF event compared to the Repair Phenotype [aHR 2.24 (95% CI: 1.57–3.19)] and noted in both participants with AKI [aHR 2.12 (95% CI: 1.35–3.34)] and without AKI [aHR 2.94 (95%CI: 1.57–5.50)]. The Dormant Phenotype was associated with higher risk of HF events only in participants without AKI. The AUC for the prediction of HF event or death at 3 years by the biomarkers was 0.76 (95% CI: 0.73–0.80), 0.77 (95% CI: 0.73–0.80) for the clinical model, and 0.80 (95% CI: 0.77–0.83) for the combined model. The addition of the biomarkers significantly improved reclassification of HF event or death. Conclusions Vascular biomarkers can be used to derive phenotypes capable of stratifying future risk of HF events in recently hospitalized patients with or without AKI.https://doi.org/10.1186/s12882-025-04169-1BiomarkersVascularAcute kidney injuryHeart failureHospitalized patientsOutcomes |
| spellingShingle | Audrey A. Shi Anna Simone Andrawis Aditya Biswas Francis P. Wilson Wassim Obeid Heather Thiessen Philbrook Alan S. Go T. Alp Ikizler Edward D. Siew Vernon M. Chinchilli Chi-Yuan Hsu Amit X. Garg W. Brian Reeves David K. Prince Pavan Bhatraju Steve G. Coca Kathleen D. Liu Paul L. Kimmel James S. Kaufman Mark W. Wurfel Jonathan Himmelfarb Chirag R. Parikh Sherry G. Mansour for the ASSESS-AKI Consortium* Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI BMC Nephrology Biomarkers Vascular Acute kidney injury Heart failure Hospitalized patients Outcomes |
| title | Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI |
| title_full | Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI |
| title_fullStr | Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI |
| title_full_unstemmed | Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI |
| title_short | Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI |
| title_sort | using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without aki |
| topic | Biomarkers Vascular Acute kidney injury Heart failure Hospitalized patients Outcomes |
| url | https://doi.org/10.1186/s12882-025-04169-1 |
| work_keys_str_mv | AT audreyashi usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT annasimoneandrawis usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT adityabiswas usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT francispwilson usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT wassimobeid usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT heatherthiessenphilbrook usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT alansgo usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT talpikizler usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT edwarddsiew usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT vernonmchinchilli usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT chiyuanhsu usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT amitxgarg usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT wbrianreeves usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT davidkprince usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT pavanbhatraju usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT stevegcoca usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT kathleendliu usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT paullkimmel usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT jamesskaufman usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT markwwurfel usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT jonathanhimmelfarb usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT chiragrparikh usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT sherrygmansour usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki AT fortheassessakiconsortium usingvascularbiomarkerstoassessheartfailureeventriskinhospitalizedpatientswithandwithoutaki |